ACADIA Pharmaceuticals officer reports RSU vesting and tax share sale
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
ACADIA Pharmaceuticals (ACAD) principal accounting officer reported equity transactions involving company stock. On 11/17/2025, 3,966 restricted stock units converted into 3,966 shares of common stock at an exercise price of $0, twice, increasing directly held shares. On 11/18/2025, 4,084 shares of common stock were sold at a weighted average price of $23.6909 to cover withholding taxes and related items in connection with restricted stock unit vesting, under a Rule 10b5-1(c) plan. Following these transactions, the reporting person directly owned 25,058 shares of ACADIA common stock. Some restricted stock units feature a multi-year vesting schedule and may vest earlier if the stock reaches specified price targets over a set trading period.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 4,084 shares ($96,754)
Net Sell
5 txns
Insider
Kihara James
Role
PRINCIPAL ACCOUNTING OFFICER
Sold
4,084 shs ($97K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 4,084 | $23.6909 | $97K |
| Exercise | Restricted Stock Units | 3,966 | $0.00 | -- |
| Exercise | Restricted Stock Units | 3,966 | $0.00 | -- |
| Exercise | Common Stock | 3,966 | $0.00 | -- |
| Exercise | Common Stock | 3,966 | $0.00 | -- |
Holdings After Transaction:
Common Stock — 25,058 shares (Direct);
Restricted Stock Units — 0 shares (Direct)
Footnotes (1)
- Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Includes 815 shares of the Issuer's common stock acquired by the reporting person on November 14, 2025 pursuant to an employee stock purchase plan. The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.69 to $23.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period.
